Institutional Fund
Aisling Capital Management LP
New York, NYCIK 17667215 filings on record
Portfolio Value
$476.29M
Q1 2026
Holdings
13
Reported positions
New Buys
1
Opened this quarter
QoQ Change
-0.5%
from $478.92M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Bridgebio Pharma Inc79.4%
- Syndax Pharmaceuticals Inc6.5%
- Monte Rosa Therapeutics Inc5.4%
- Bicara Therapeutics Inc2.4%
- Bridgebio Oncology Therapeut1.9%
- Compass Pathways PLC1.7%
- Other2.9%
Portfolio Holdings
13 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Bridgebio Pharma Inc | 5.09M | $377.95M | 79.4% | 0 | Held |
| 2 | Syndax Pharmaceuticals Inc | 1.32M | $30.76M | 6.5% | 0 | Held |
| 3 | Monte Rosa Therapeutics Inc | 1.56M | $25.59M | 5.4% | +83.3K | Added |
| 4 | Bicara Therapeutics Inc | 568.9K | $11.32M | 2.4% | 0 | Held |
| 5 | Bridgebio Oncology Therapeut | 1.02M | $9.11M | 1.9% | +453.4K | Added |
| 6 | Compass Pathways PLC | 1.43M | $7.92M | 1.7% | +233.9K | Added |
| 7 | Scholar Rock Hldg Corp | 77.0K | $3.79M | 0.8% | 0 | Held |
| 8 | Biomea Fusion Inc | 2.05M | $3.13M | 0.7% | 0 | Held |
| 9 | Eupraxia Pharmaceuticals Inc | 325.0K | $2.35M | 0.5% | +325.0K | New |
| 10 | Urogen Pharma Ltd | 108.0K | $1.94M | 0.4% | 0 | Held |
3 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio